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Abstract
Background: Intrinsic to “Patient-Centered Care” is being respectful and responsive to individual patient preferences,
expressed needs, and personal values. Establishing a patient’s preferences for active and aggressive intervention is
imperative and foundational to the development of advance care planning. With the increasing awareness and
acceptance of palliative philosophies of care, patients with advanced cancer are increasingly transitioning from active
and aggressive medical management (AAMM) to conservative palliative management (CPM).
Methods: A cross-sectional study based on a prospective and sequential case series of patients referred to a
regional palliative medicine consultative program was assembled between May 1, 2005 and June 30, 2006. Patients
and/or their substitute decision makers (SDM) completed a questionnaire, at baseline, that assessed their
preferences for AAMM en route to their eventual deaths. Seven common interventions constituting AAMM were
surveyed: cardiopulmonary resuscitation (CPR) & mechanical ventilation (MV), chemotherapy, antibiotics,
anticoagulants, blood transfusions, feeding tubes, and artificial hydration. Multivariable analyses were conducted on
the seven interventions individually as well as on the composite score that summed preferences for the seven
interventions.
Results: 380 patients with advanced cancer agreed to participate in the study. A trend to desire a mostly
conservative palliative approach was noted as 42% of patients desired one or fewer interventions. At baseline,
most patients and their SDM’s were relatively secure about decisions pertaining to the seven interventions as the
rates of being “undecided” ranged from a high of 23.4% for chemotherapy to a low of 3.9% for feeding tubes.
Multivariable modeling showed that more AAMM was preferred by younger patients (P < 0.0001), non-Caucasians
(P = 0.042), patients with higher baseline Palliative Performance Scale scores (P = 0.0002) and where a SDM was
involved in the decision process (p = 0.027). Non-statistically significant trends to prefer more AAMM was observed
with male gender (p = 0.077) and higher levels of the Charlson Comorbidity index (p = 0.059). There was no
association between treatment preferences and cancer class.
Conclusions: Although the majority of patients with advanced cancer in this study expressed preferences for CPM,
younger age, higher baseline PPSv2, and involvement of SDMs in the decision process were significantly associated
with preferences for AAMM.
Background
The publication of the landmark SUPPORT (Study to
Understand Prognoses and Preferences for Outcomes and
Risks of Treatments) controlled trial in 1995 served to
highlight major problems with end-of-life decision making
related to weaknesses in advance care planning and less
than optimal communication between physicians and
their patients and families [1]. Among many findings,
decreased adherence with patient preferences was demon-
strated [1]. SUPPORT demonstrated greater emphasis on
the provision of burdensome and ultimately ineffective/
futile interventions to patients with advanced illness near
the end-of-life [1]. Consequently, patients experienced
poor pain and symptom management with resultant
decreased quality of life [1]. SUPPORT has subsequently
served as a major catalyst to improve end-of-life commu-
nication as well as promoting the development of Palliative
Care as a specialty. The shortfalls identified in SUPPORT
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sidered most important by patients and their families at
end-of-life: pain and symptom management, good physi-
cian-patient communication, being prepared for what to
expect, achieving a sense of completion in life, clear deci-
sion-making, and being treated as a “whole person” [2].
All of these are now regarded among the core values and
tenets of Palliative Care.
Patients with advanced cancer may be regarded as being
in transition from active and aggressive medical manage-
ment (AAMM) to conservative palliative management
(CPM). Prior to the advent of palliative care, advanced
cancer patients would generally continue with AAMM
until their death. “AAMM” may be described and defined
as consisting of all active medical treatments or active
interventions that deal with physiologic derangements or
medical complications experienced by the patient. The
prime goal and intent of AAMM is to potentially sustain
or prolong life. Hence, many authors have termed them
“Life-sustaining” or “Life-prolonging” treatments or inter-
ventions. It may be argued that when successful and
appropriately applied, such treatments may also improve
quality of life. However, the later in the disease trajectory
such treatments are employed, the less likely they are to
be effective and the more likely they will be burdensome.
An example of this situation is using feeding tubes where
there is evidence of efficacy only for those patients under
consideration for a potentially curative surgical resection
of their upper gastrointestinal cancers [3]. “CPM” may be
described as all efforts to maintain comfort, dignity, and
quality of life through the use of pain and symptom man-
agement, and generally, without the use of potentially life-
prolonging measures. Many authors have dubbed this
approach as “Comfort Care” [4] or “Comfort Measures
Only” [5]. The prime goal and intent of CPM is to maxi-
mize comfort, dignity, and quality of life.
Healthcare is evolving from the traditional paternalis-
tic medical model to a more autonomous and patient-
directed model. Recently, this contemporary approach
was termed “Patient-Centered Care” (PCC). According
to the Picker Institute [6] and the Institute of Medicine
[7], PCC is health care that is respectful of and respon-
sive to individual patient preferences, expressed needs,
and personal values [6-8]. PCC also emphasizes the
need for effective communication, education, and infor-
mation-sharing with patients and their family and
friends, as well as facilitating integration of care and
appropriate and timely transitioning. PCC promotes
ethical health care that strives to improve patient satis-
faction. Intrinsic to PCC is optimal communication
between patients and clinicians. A recent systematic
review concluded that patients vary in their preferences
for communication style and in their desire for partici-
pation in decision making, thereby indicating the need
for individualization [9]. Good communication between
patients, their family members, and clinicians allows for
exploration of values and goals of care, and promotes
the discussion of preferences for the patient’s future
care. Written advance directives formalize these prefer-
ences and include living wills and designation of durable
powers of attorney for health care, that specify health
care proxies. There is great variability in the range and
extent of intervention that patients with advanced can-
cer desire. When asked, some patients simply state
“Iw a n te v e r y t h i n gd o n e ” or “I want to fight until the
end”. Such statements should not simply be taken at
face value, but should be further explored and discussed
within the context of the patient’s disease and associated
prognosis [10]. Physicians, too, need to be clear about
their statements to patients. For instance, the use of
euphemisms to “soften the shock of bad news” may con-
fuse or mislead patients [11].
The decision making process involved in healthcare
may be divided into four major components: physician
knowledge of patient medical history; physician disclo-
sure of treatment choices; discussion of treatment
choices; and selection of treatment choice [12]. Several
models of decision making have been described. In the
paternalistic model, physicians perform information
management, assess options, and make treatment deci-
sions for patients without consideration of patient pre-
ferences [13]. In the informed or consumer model,
physicians provide all relevant information to their
patients, and patients alone assess their options and
make the final decision. The physician in this model
serves as the technical expert to provide information
and facilitate decisions made by a fully-autonomous
patient [14]. The shared model essentially merges these
two models into one where patients and physicians par-
ticipate equally in all stages of decision making [15].
Moreover, the physician and other healthcare clinicians
explore patient preferences and ensure that they are
congruent with “evidence-based care” [16].
This study investigates the preferences of advanced
cancer patients and their SDM’s for commonly-offered
active and aggressive medical therapies like cardiopul-
monary resuscitation (CPR) & mechanical ventilation
(MV), chemotherapy, antibiotics, anticoagulants, blood
transfusions, feeding tubes and artificial hydration. This
study serves to evaluate the correlations that exist
between preferences for pursuing active and aggressive
medical interventions and various patient characteristics,
demographics, and other clinical parameters.
Methods
Study Population
A consecutive cohort of all new referrals to a regional
palliative medicine program in Toronto, Canada was
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30, 2006. Referrals included both cancer patients and
patients with advanced non-cancer disorders. Patients
were referred for consideration of palliative medical
management and eventual end-of-life care. Patients were
assessed either in their homes or in the hospital. This
study focuses on the cancer patients. All patients or
their substitute decision makers (SDM) provided con-
sent to have their clinical data registered in a research
database. The data collected was entered on a custo-
mized Microsoft™ Access 2007 database. This was done
on an accrual basis.
Measurement
All patients were examined within twenty-four hours of
the initial referral. The initial consultation was desig-
nated as the baseline for the study. At baseline, basic
demographic data was collected, the primary cancer
diagnosis was recorded, and performance status was
measured using the Palliative Performance Scale (PPSv2)
[17]. PPSv2 measures performance status between 0%
(patient dead) and 100% (patient completely functional)
and is highly correlated with the Karnofsky Performance
Status scale [18].
Upon completion of the history taking and physical
examination, a questionnaire was administered (Figure 1),
within the process of an interactive discussion with the
patient and/or SDM. At the outset, it was ensured that the
patient was mentally capable and fluent in English. In
cases where the patient was mentally incapable the SDM
was asked to express preferences. When English fluency
was inadequate an interpreter was enlisted. The purpose
of this questionnaire was to ascertain the patient’s prefer-
ences for active interventions such as CPR together with
MV, future chemotherapy, antibiotics for future infective
complications, anticoagulants for future thromboembolic
complications, blood transfusions for anemia and/or
hemorrhage, feeding tubes and artificial hydration. The
seven questions were discussed in a conversational man-
ner while placing emphasis on the context of their dis-
eases. Regarding CPR & MV, patients were informed of
data that reflects less than 7% survival to discharge for
advanced cancer patients suffering a cardio respiratory
arrest [19]. The decisions regarding the listed interventions
were recorded as “withhold intervention”, “desires inter-
vention”,o r“undecided”. In the case of CPR & MV, cases
that were “undecided” were defaulted into the “desires
intervention” category. The rationale for this default posi-
tion was that, in the event of cardiac and/or respiratory
arrest, only the patients who specifically and definitively
opted to withhold intervention should forego CPR & MV.
If the patient or SDM inquired about patient life expec-
tancy, a median life expectancy was quoted as estimated in
relation to their baseline PPSv2 as follows: PPSv2 10-20
= median survival of 1 week; PPSv2 30-50 = median survi-
v a lo f1m o n t h ;a n dP P S v 2≥ 60 = median survival of
3 months [18]. This was justified by a recent study that
showed improved satisfaction when prognostic data was
provided [20]. Baseline preferences were not irrevocable as
patient preferences were revisited as indicated by the
needs of the patient or SDM. This acknowledges that pre-
ferences may vary over the disease trajectory [21].
The primary cancer diagnoses were classified as gas-
trointestinal (gastric, esophageal, small intestine, color-
ectal, biliary, pancreatic, liver), lung (non-small cell,
small cell, mesothelioma), genitourinary (prostate, renal,
bladder, ureter), breast, hematologic (all leukemias, lym-
phomas, myeloma), gynecologic (cervix, ovarian, uter-
ine), and others (sarcoma, carcinoid, primary brain
tumors, primary skin cancers, primary head and neck
cancers, metastatic adenocarcinoma of unknown pri-
mary source).
After their baseline assessment, patients were treated
in a supportive manner while respecting and complying
with their expressed preferences, and were followed
until their deaths. The Charlson Comorbidity Index
(CCI), based upon parameters present at the time of
referral, was calculated retrospectively according to pub-
lished guidelines [22,23].
Ethical Considerations
This study involved analysis of a palliative medicine
database developed by the principal author. The data-
base was anonymized and bears no links to patients.
This study was approved by the research ethics board of
the William Osler Health Centre in Toronto, Canada.
Statistical Analysis
Only cancer patients (n = 380) were included in the
study. Data was exported from the Microsoft™ Access
2007 database into S-Plus 6.2 for Windows for statistical
analysis. For each intervention mutivariable logistic
regression models were fitted to explore correlates of 1)
uncertainty versus certainty in whether the intervention
was wanted or not and 2) in those who were decided,
desiring the intervention versus not desiring it. The fol-
lowing factors were considered as explanatory variables:
the patient’s age, gender (male, female), race (Caucasian,
non-Caucasian), PPSv2, CCI and cancer type (gastroin-
testinal, lung, genitourinary, breast, hematologic, gyneco-
logic, others) as well as the decision-maker regarding the
interventions (patient alone, patient and SDM, SDM
alone). Age, PPSv2 and CCI entered the models as con-
tinuous variables, Significance were assessed by fitting
nested models and testing the drop in deviance with X
2
tests. A composite score reflecting the overall desire for
AAMM was constructed by totaling the number of inter-
ventions desired by each patient. Any undecided entries
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sponds to assigning a probability of one-half to the event
of an undecided intervention being accepted. Correlates
of the composite score were explored using multivariable
linear regression. For the modeling the composite score
was expressed as a proportion out of 7 and the variance
stabilizing transformation for proportions (inverse sine of
the square root of the proportion) was applied to
improve the statistical properties of the outcome variable.
Predicted values from the model were obtained for
selected variable values by setting the rest of the variables
to their mean value (age = 72.9, ppsv2 = 50, CCI = 9) or
to the most common value (gender = male, race =
Caucasian, diagnosis = GI, decision maker= patient) and
transforming back from the inverse sine square root
transformation to proportions.
Results
Patient Characteristics
380 cancer patients were referred to the program during
the study period. Slightly over half of the patients (54.5%)
were male. The mean age at referral was 73 years (stan-
dard deviation 13 years, range 19 to 99). 76.6% of patients
were 65 years or older while 23.4 were less than 65 years
Figure 1 Questionnaire to Assess Patient Preferences for Intervention.
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The most frequent primary cancer diagnoses were gas-
trointestinal (28.7%) and lung cancer (25.2%), followed by
genitourinary (8.7%), breast (7.1%), gynecologic (5.8%)
and hematologic (5.5%). 61.1% of patients presented with
PPSv2 of greater than or equal to 50% while 38.9% pre-
sented with a PPSv2 of less than 50%. 59.2% of patients
presented with a CCI of greater than or equal to 9 while
40.8% presented with a CCI of less than 9.
Patient Certainty
At baseline, most patients and their SDM’s were rela-
tively secure about decisions pertaining to the seven
interventions presented given that the rates of being
“undecided” ranged from a high of 23.4% for chemother-
apy to a low of 3.9% for feeding tubes (Table 1). In the
multivariable models (Table 1), indecision was not
related to the explanatory variables age, gender, race,
PPSv2, CCI, cancer type or decision-maker for any of the
interventions (all model P > 0.05) except for artificial
hydration (model P = 0.037). Males were significantly
more undecided about artificial hydration than females
(odds ratio 2.61, P = 0.01), as were non-Caucasians
versus Caucasians (odds ratio 2.44, P = 0.03).
Patient Preferences
In decided patients, interventions that were most often
desired by advanced cancer patients were: Anticoagu-
lants (52.9%), Antibiotics (50.9%), Artificial Hydration
(49.4%) and Blood transfusions (44.7%). Less frequently
desired were Feeding tubes (34.0%), Chemotherapy
(38.1%), and CPR/MV (25.5%). Table 2 shows the corre-
lates of desiring each intervention. The overall model P-
values were all significant, indicating that each model
explained a statistically significant amount of the varia-
tion in each outcome.
74.5% of decided patients expressed the desire to with-
hold CPR & MV. Patients who desired this intervention
tended to be younger (odds ratio 0.67 for every ten year
increase in age, P < 0.0001) and to have a higher perfor-
mance status (odds ratio 1.32 for every ten units
increase in PPSv2, P = 0.021).
61.9% of decided patients expressed the desire to with-
hold further chemotherapy if offered. Patients who
desired this intervention tended to be younger (odds
ratio 0.68 per ten year increase in age, P = 0.0007), to be
non-Caucasian (odds ratio 4.16, P = 0.0004), to have a
higher performance status (odds ratio 1.97 for every ten
units increase in PPSv2, P < 0.0001), to have higher CCI
(odds ratio 1.17 for every unit increase, P = 0.016) and to
have a SDM involved in the decision (odds ratios 3.65
and 4.24 for patient/SDM and SDM alone, P = 0.003).
49.1% of decided patients expressed the desire to with-
hold future antibiotic therapy. Patients who desired this
intervention tended to be younger (odds ratio 0.72 for
every ten year increase in age, P = 0.0004) and to have a
higher performance status (odds ratio 1.45 for every ten
units increase in PPSv2, P = 0.001).
41.7% of decided patients expressed the desire to with-
hold future anticoagulant therapy. Patients who desired
this intervention tended to be younger (odds ratio 0.74
per ten year increase in age, P = 0.002), to have a higher
performance status (odds ratio 1.55 for every ten units
increase in PPSv2, P = 0.0001) and to have a SDM
involved in the decision (odds ratios 1.84 and 2.98 for
patient/SDM and SDM alone, P = 0.031).
55.3% of decided patients expressed the desire to with-
hold future blood transfusions. Patients who desired this
intervention tended to be younger (odds ratio 0.72 for
every ten year increase in age, P = 0.0002) and to have a
higher performance status (odds ratio 1.34 for every ten
units increase in PPSv2, P = 0.007).
66% of decided patients expressed the desire to with-
hold the future insertion of a feeding tube. Patients who
desired this intervention tended to be younger (odds
ratio 0.72 for every ten year increase in age, P = 0.0004),
to be male (odds ratio 1.81, P = 0.032), to have a higher
performance status (odds ratio 1.43 for every ten units
increase in PPSv2, P = 0.002), to have a higher CCI (odds
ratio 1.13 for every unit increase, P = 0.016) and to have
a SDM involved in the decision (odds ratios 2.92 and
2.76 for patient/SDM and SDM alone, P = 0.007).
50.8% of decided patients expressed the desire to with-
hold artificial hydration. Patients who desired this inter-
vention tended to be younger (odds ratio 0.70 for every
ten year increase in age, P = 0.0001), to have a higher
performance status (odds ratio 1.47 for every ten units
increase in PPSv2, P = 0.0007) and to have a SDM
involved in the decision (odds ratios 1.87 and 2.84 for
patient/SDM and SDM alone, P = 0.04).
Composite Score
The composite score reflects the number of interven-
tions desired by each patient, counting undecided as 0.5.
There was a tendency towards the extremes in the com-
posite score, with 41.6% of patients wanting one or
fewer interventions and 23.9% wanting six or more
interventions. Table 3 shows the multivariable regres-
sion results for the transformed composite score. Over-
all the model was significant (model P < 0.0001, R
2 =
14.2%). The number of interventions desired decreased
with increasing age (P < 0.0001), was higher for non-
Caucasians than Caucasians (P = 0.042), increased with
increasing PPSv2 and was greater when a SDM was
involved in the decision (P = 0.027). Non-statistically
significant trends to prefer more AAMM was observed
with male gender (p = 0.077) and higher levels of the
Charlson Comorbidity index (p = 0.059). The patient’s
Maida et al. BMC Cancer 2010, 10:592
http://www.biomedcentral.com/1471-2407/10/592
Page 5 of 10cancer diagnosis did not demonstrate any statistically
significant trends with respect to a preference for more
interventions.
Discussion
T h i si st h ef i r s ts t u d yt oe v a l u a t et h ep r e f e r e n c e so f
patients with advanced cancer referred to a palliative
medicine consultative program for a group of seven com-
mon active and aggressive interventions while en route to
their eventual death. Overall, there was a trend to desire
a mostly-conservative palliative approach, as nearly 42%
of patients desired one or fewer interventions. At base-
line, most patients and their SDM’s were relatively secure
about decisions pertaining to the seven interventions
presented, given that the rates of being “undecided” ran-
ged from a high of 23.4% for chemotherapy to a low of
3.9% for feeding tubes.
This study demonstrated that older age was associated
with a greater tendency to withhold each of the poten-
tially life-prolonging measures offered. This is consistent
with previously published reports [24,25]. One study
showed that younger patients suffering from advanced
cancer, with dependent children, are more likely to desire
aggressive management, within an acute hospital setting
[26]. Unfortunately, this was associated with reduced
quality of life in their last week of life [26].
Male gender was associated with a greater tendency
to desire feeding tubes but not the other active and
Table 1 Correlates of being undecided versus decided regarding each intervention: multivariable logistic regression
model results for each intervention
Chemo- Therapy
N = 380
Anti- biotics
N = 380
Anti- coagulants
N = 380
Blood transfusion
N = 380
Feeding tubes
N = 380
Artificial hydration
N = 380
Number (%) undecided
about intervention
89 (23.4) 56 (14.7) 51 (13.4) 40 (10.5) 15 (3.9) 51 (13.4)
Age
Odds ratio: per 10 yr
increase
0.94 1.03 0.84 1.09 1.04 1.01
P-value 0.512 0.784 0.148 0.542 0.865 0.917
Gender
Odds ratio: Male vs. Female 1.31 1.96 1.23 1.61 1.38 2.61
P-value 0.347 0.054 0.563 0.248 0.588 0.011
Race
Odds ratio: Non- vs.
Caucasian
0.75 1.77 1.46 1.81 1.67 2.44
P-value 0.462 0.168 0.374 0.214 0.481 0.034
Cancer Diagnosis
Odds ratio:
Lung vs. GI 1.2 0.97 0.97 1.9 1.62 1.04
GU vs. GI 1.29 0.54 0.98 1.38 1.21 1.1
Breast vs. GI 1.1 1.62 0.85 2.07 0 1.72
Hematologic vs. GI 2.23 2.06 0.89 1.8 2.25 2.56
GYN vs. GI 3.26 2.36 1.89 3.16 1.39 2.37
Other vs. GI 1.56 0.65 0.59 0.49 1.49 0.56
P-value 0.395 0.349 0.804 0.218 0.882 0.317
PPSv2
Odds ratio: per 10 unit
increase
0.91 1.01 0.77 0.99 1.07 0.83
P-value 0.433 0.964 0.083 0.971 0.801 0.214
CCI
Odds ratio: per unit increase 0.92 0.89 0.9 0.96 0.83 0.9
P-value 0.104 0.066 0.123 0.553 0.073 0.117
Decision maker
Odds ratio:
Pat/SDM vs. Pat 1.09 1.69 1.21 1.7 1.2 1.7
SDM vs. Pat 1.42 1.28 0.5 1.22 2.8 0.82
P-value 0.701 0.445 0.137 0.504 0.498 0.177
Model P-value 0.147 0.291 0.430 0.491 0.688 0.037
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gender disparity in this study is consistent with a pre-
viously published report of a mixed (cancer and non-
cancer) cohort of patients with advanced illness [4].
A literature search conducted on Ovid MEDLINE,
PubMed, The Cochrane Library, CINAHL, and Health-
STAR databases between 1997 and July 2010 failed to
locate reports that focused on solely on cancer.
This study demonstrated that non-Caucasian patients
were more desirous of chemotherapy and they tended to
desire more interventions overall according to the compo-
site score analysis. A recent oncology study demonstrated
that more Black patients (45%) and Hispanic patients
(34%) desired potentially life-prolonging measures than
White patients (14%) even if they had only a few days to
live [27]. Another study involving a combination of cancer
and noncancer terminal illnesses also showed that more
Black patients (28%) and Hispanic patients (21.2%) than
white patients (15%) desired potentially life-prolonging
drugs, even if they caused them to “feel worse all the time”
[28]. In the same study, fewer Black patients (49%) and
Hispanic patients (57%) than White patients (74%) desired
“potentially life-shortening palliative drugs” [28]. Another
study demonstrated that Blacks and Hispanics are less
Table 2 Correlates of desiring an intervention versus not desiring it: multivariable logistic regression model results for
each intervention
CPR & MV* N
= 380
Chemo-
therapy
N = 291
Anti-biotics N
= 324
Anti-coagulants
N = 329
Blood
transfusions
N = 340
Feeding tubes
N = 365
Artificial hydration
N = 329
Number (%) desiring
intervention
97 (25.5) 111 (38.1) 165 (50.9) 174 (52.9) 152 (44.7) 124 (34) 162 (49.2)
Age
Odds ratio: per 10 yr
increase
0.67 0.68 0.72 0.74 0.72 0.72 0.7
P-value < 0.0001 0.0007 0.0004 0.002 0.0002 0.0004 0.0001
Gender
Odds ratio: Male vs.
Female
1.33 1.58 1.37 1.49 1.29 1.81 1.38
P-value 0.324 0.145 0.241 0.138 0.339 0.032 0.237
Race
Odds ratio: Non- vs.
Caucasian
1.71 4.16 1.46 1.67 1.19 1.69 1.53
P-value 0.126 0.0004 0.310 0.172 0.613 0.131 0.255
Cancer Diagnosis
Odds ratio: Lung vs. GI 1.25 0.86 0.81 0.99 0.82 1.19 0.73
GU vs. GI 0.62 0.71 1.03 1.26 1.17 0.9 1.13
Breast vs. GI 0.94 0.99 0.92 1.27 1.38 1.13 1.07
Hematologic vs. GI 0.72 0.47 0.45 0.42 0.66 0.4 0.28
GYN vs. GI 1.1 1.55 1.06 0.85 1.05 1.53 1.06
Other vs. GI 0.64 0.6 0.73 0.69 0.79 1.6 0.74
P-value 0.632 0.795 0.878 0.627 0.882 0.510 0.494
PPSv2
Odds ratio: per 10 unit
increase
1.32 1.97 1.45 1.55 1.34 1.43 1.47
P-value 0.021 < 0.0001 0.001 0.0001 0.007 0.002 0.0007
CCI
Odds ratio: per unit
increase
1.09 1.17 1.08 1.05 1.09 1.13 1.08
P-value 0.113 0.016 0.153 0.294 0.077 0.016 0.128
Decision maker
Odds ratio:
Pat/SDM vs.Pat 1.89 3.65 1.48 1.84 1.65 2.92 1.87
SDM vs. Pat 1.7 4.24 2.34 2.98 1.84 2.76 2.84
P-value 0.212 0.003 0.134 0.031 0.239 0.007 0.040
Model P-value 0.0001 < 0.0001 0.0001 < 0.0001 0.002 < 0.0001 < 0.0001
* Cardiopulmonary Resuscitation & Mechanical Ventilation.
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and Blacks express greater discomfort when discussing
death [29]. In one study, Blacks were less likely than Cau-
casians to complete an advance directive (35.5% vs. 67.4%,
p < 0.001), and they tended to have less favourable beliefs
about hospice care as well as a general mistrust of the
health care system [29].
Although our study did not assess the religion or
spiritual correlates of patient preferences, a recent study
demonstrated that higher levels of religiousness was
associated with desiring all aggressive measures (OR
1.96; 95% CI 1.08-3.57) with the intent to prolong life
[30]. In addition, African-Americans and Hispanics
rated religion as important more frequently than Cauca-
sians [30].
Performance status, as measured with PPSv2, was
highly-correlated with preferences. For each intervention
higher PPSv2 was significantly associated with increased
odds of desiring the intervention and it was also asso-
ciated with higher composite scores. These results are
Table 3 Correlates of the composite score reflecting the overall desire for AAMM. The composite score is the number
of interventions desired by each patient, scoring any undecided entries as 0.5. For modeling purposes the score was
expressed as a proportion out of seven and a variance stabilizing transformation applied
Explanatory variable Regression Coefficient P-value Predicted Proportion of Interventions Desired*
Age -0.09 per 10 year increase < 0.0001
30 years 0.69
40 years 0.60
50 years 0.51
60 years 0.42
70 years 0.34
80 years 0.25
Gender 0.077
Male 0.107 0.31
Female reference 0.22
Race 0.042
Caucasian reference 0.31
Non-Caucasian 0.162 0.47
Cancer Diagnosis 0.905
GI reference 0.31
Lung -0.001 0.31
GU -0.022 0.29
Breast 0.022 0.33
Hematologic -0.116 0.21
GYN 0.040 0.35
Other -0.075 0.24
PPSv2 0.095 per 10 unit increase 0.0002
20 0.09
30 0.15
40 0.23
50 0.31
60 0.40
70 0.50
CCI 0.021 per unit increase 0.059
7 0.27
9 0.31
11 0.35
Decision maker 0.027
Patient reference 0.31
Patient/SDM 0.173 0.48
SDM 0.245 0.55
*For each variable shown, predicted proportions were obtained by setting the rest of the variables to their mean value (continuous variables) or most common
value (categorical variables) and back-transforming.
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Page 8 of 10intuitive as patients with higher PPSv2 are more func-
tional, less dependent, and also have a longer survival
period relative to patients with lower levels of PPSv2. A
recent systematic review confirmed that PPSv2 is highly
correlated with survival in cancer patients and is useful
in establishing prognoses [31].
Comorbid illness as measured with the Charlson
Comorbidity Index (CCI) was associated with a greater
desire for chemotherapy and feeding tubes. These trends
may seem paradoxical as one might expect that those
patients with the highest CCIs are among the “sickest”
and thus more likely to adopt less AAMM. A potential
explanation may be that such patients are so accus-
tomed to receiving medical “micromanagement” addres-
sing all of their comorbid factors that they have a
propensity to desire AAMM, perhaps, based on a condi-
tioned response.
The involvement of Substitute Decision Makers
(SDM) in establishing preferences for active and aggres-
sive intervention was associated with greater desire to
pursue AAMM. The composite intervention analysis
(Table 3) demonstrated that this trend was greater when
SDMs acted alone versus SDMs assisting the patient.
The individual intervention analysis (Table 2) showed a
greater tendency for AAMM when the SDM acted alone
versus SDMs assisting the patient for all interventions
except chemotherapy and feeding tubes. Although the
explanation of this phenomenon is unclear, it may rest
with the supposition that SDMs base such decisions on
what they might decide for themselves at that instant
[32]. Given that SDMs are generally healthier than their
patient counterparts, it is more likely that they will elect
for a more active and aggressive mode of care [32].
This study has a number of weaknesses. Data was col-
lected from a single palliative program and employed a
questionnaire (Figure 1) that had not undergone reliabil-
ity or validity studies. It only considered preferences
regarding withholding active and aggressive interven-
tions while not adjusting for those patients who were
receiving those interventions at baseline nor those that
later decided to withdraw active interventions. In addi-
tion, there was no data on socioeconomic status or stra-
tification for the different forms of the individual
interventions. Although there was no randomization,
this study was nonetheless based on a large prospective
and sequential case series.
Conclusion
Exploring patient preferences for active intervention is
central and intrinsic to delivering “Patient-Centered
Care” that is consistent with the ethical principles of
informed consent and autonomy [33]. Futile treatments
remain highly utilized among advanced cancer patients
and are associated with significant implications for
healthcare economics [34]. Allowing patients to express
their preferences, has the potential to reduce the volume
of futile treatments, thus promoting financial sustain-
ability of our health care systems while addressing the
ethical principle of distributive justice [33].
This study exemplifies the first stage of shared decision
making process, namely, establishing patient treatment
preferences. This information is vital and foundational in
the development of advance directives as well as allowing
for optimal planning for the patient’s future healthcare.
This study demonstrates that the majority of advanced
cancer patients prefer to adopt CPM over AAMM.
Therefore, it behooves physicians and other healthcare
professionals to explore the preferences for active and
aggressive intervention among their patients suffering
from all forms of advanced illness, including those with
cancer. It should never be assumed that patients desire
continuation of active and aggressive interventions for
the balance of their lives. Moreover, patients and their
SDMs should be counseled around the fact that although
active and aggressive measures may be beneficial and
potentially life-prolonging during the earlier phases of
their malignant disease, they generally become increas-
ingly ineffective, burdensome, and futile later in the dis-
ease trajectory. Hopefully, this information may be
elicited at an earlier stage rather than waiting for the
patient to be referred for palliative medical management.
Moreover, eliciting this information at an earlier stage
may enhance the likelihood that the patient will articulate
their own unassisted views on treatment preferences.
Finally, the determination of clearly articulated goals and
objectives of care may facilitate earlier transition to a
completely palliative mode of care with the potential for
improvements in comfort, dignity, and quality of life.
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